The present Hepatocellular Carcinoma market size is mainly dominated by the protein Kinase inhibitor i.e., Nexavar (Sorafenib) developed by Bayer is considered the first line of treatment. Followed by the second line of treatments and off label Chemotherapies.
Opdivo, leading drug of
Bristol-Myers Squibb approved only in the US and Stivarga developed by Bayer are
the two FDA-approved Hepatocellular Carcinoma treatment drugs that have so far
created a positive effect on HCC Market.
Hepatocellular Carcinoma Market Trends
The dynamics of Hepatocellular Carcinoma market is anticipated to change in the coming years owing to the expected launch of emerging therap...
